Biopharma & Life Sciences
Jade Biosciences, Inc. Executive Compensation (FY25)
JBIO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Tom Frohlich |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Jade Biosciences, Inc. brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of October 28, 2026Latest filing (DEF 14A): April 28, 2026
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
111 figures on this page: 110 cited to the filing that reported them, 1 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Tom Frohlich: $1,364,396 → $9,799,759
Frequently asked questions
Answers drawn from the data on this page.
Who is Jade Biosciences, Inc.'s chief executive and what were they paid?
Tom Frohlich, Chief Executive Officer, President and Director, received $9,799,759 in total compensation for fiscal 2025. Frohlich's total was up from the $1,364,396 reported for fiscal 2024.
Which companies are in Jade Biosciences, Inc.'s peer group?
Companies named in the disclosed peer group include ACELYRIN, Inc., Alumis Inc., Apogee Therapeutics, Inc., Astria Therapeutics, Inc. and CARGO Therapeutics, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Marinus Verwijs Senior Vice President, CMC | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Timothy Noyes Chief Executive Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
George Eldridge Chief Financial Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Timothy Noyes Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Timothy Pigot Chief Commercial Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
George Eldridge Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Timothy Noyes Former Chief Executive Officer | ◇ | — | — | ◇ | — | — | — | ◇ |
Tom Frohlich Chief Executive Officer, President and Director | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Andrew King President, Research and Development | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Tom Frohlich Chief Executive Officer, President and Director | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Andrew King President, Research and Development | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Bradford Dahms Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Timothy Noyes Former Chief Executive Officer Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Tom Frohlich | Option | ◇ | — | ◇ | 1/29/2035 |
| Option | ◇ | — | ◇ | 1/29/2035 | |
| Option | ◇ | — | ◇ | 10/12/2034 | |
| Andrew King | Option | ◇ | — | ◇ | 1/29/2035 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/29/2035 | |
| Option | ◇ | — | ◇ | 10/29/2034 | |
| RSU | ◇ | = | — | — | |
| Bradford Dahms | Option | ◇ | — | ◇ | 7/14/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Andrew King
President, Research and Development · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Bradford Dahms
Chief Financial Officer · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Eric Dobmeier, J.D | ◇ | — | ◇ | — | — | — | ◇ |
Erin Lavelle | ◇ | — | ◇ | — | — | — | ◇ |
Lawrence Klein, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Tomas Kiselak | ◇ | — | ◇ | — | — | — | ◇ |
Christopher Cain, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Chris Cain | ◇ | — | ◇ | — | — | — | ◇ |
Mark Iwicki | ◇ | — | — | — | — | — | ◇ |
Allison Dorval | ◇ | — | — | — | — | — | ◇ |
Habib J. Dable | ◇ | — | — | — | — | — | ◇ |
Joshua Resnick, M.D | ◇ | — | — | — | — | — | ◇ |
David Grayzel, M.D | ◇ | — | — | — | — | — | ◇ |
Donald J. Santel | ◇ | — | — | — | — | — | ◇ |
Tom Frohlich served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- ACELYRIN, Inc. SLRN
- Alumis Inc. ALMS
- Apogee Therapeutics, Inc. APGE
- Astria Therapeutics, Inc. ATXS
- CARGO Therapeutics, Inc. CRGX
- Contineum Therapeutics, Inc. CTNM
- Dianthus Therapeutics, Inc. DNTH
- Entrada Therapeutics, Inc. TRDA
- Janux Therapeutics, Inc. JANX
- Kymera Therapeutics, Inc. KYMR
- Kyverna Therapeutics, Inc. KYTX
- Lyell Immunopharma, Inc. LYEL
- Oruka Therapeutics, Inc. ORKA
- Pliant Therapeutics, Inc. PLRX
- Prime Medicine, Inc. PRME
- Septerna Therapeutics, Inc. symbol not shown
- Spyre Therapeutics, Inc. SYRE
- Third Harmonic Bio, Inc. THRD
- Upstream Bio, Inc. UPB
- Zenas BioPharma, Inc. ZBIO
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Tom Frohlich (Chief Executive Officer, President and Director), FY2025 total compensation $9,799,759 (base salary $621,970) [exec_comp, SEC accession 0001193125-26-187059, filed 2026-04-28]What this page does not include
Everything above is a fact Jade Biosciences, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Jade Biosciences, Inc. sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
111 figures on this page: 110 cited to the filing that reported them, 1 calculated from figures it prints.
110 cited to the filing
1 calculated from the filing
Documents cited
- 0001193125-26-187059DIRECTOR COMPENSATION · OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END · Proxy severance section · SUMMARY COMPENSATION TABLE
- 0001798749-24-000022
- 0001798749-23-000028
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Jade Biosciences, Inc. executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/JBIO (accessed 2026).
Short form: data: Velarion
The Jade Biosciences, Inc. brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Jade Biosciences, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Jade Biosciences, Inc. discloses
The companies named in JBIO's own disclosed peer group.
Alumis Inc.Apogee Therapeutics, Inc.Astria Therapeutics, Inc.CARGO Therapeutics, Inc.Contineum Therapeutics, Inc.Dianthus Therapeutics, Inc.Entrada Therapeutics, Inc.Janux Therapeutics, Inc.Kymera Therapeutics, Inc.Kyverna Therapeutics, Inc.Lyell Immunopharma, Inc.Oruka Therapeutics, Inc.Pliant Therapeutics, Inc.Prime Medicine, Inc.Spyre Therapeutics, Inc.Upstream Bio, Inc.Zenas BioPharma, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}